Creating models to improve treatments for chronic myelomonocytic leukemia
Official title: Developing and credentialing patient-derived xenograft models to advance therapeutic approaches for chronic myelomonocytic leukemia
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10798431 · Data updated 2026-11-12
This study is looking at chronic myelomonocytic leukemia (CMML) to find new treatments by using special models that mimic the disease, and it also explores how a certain type of immune cell might affect how the disease behaves and responds to therapy.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | August 12, 2019 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $453,813 |
| NIH project number | 4R37CA234021-06 |
| Project ID | NIH-10798431 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with chronic myelomonocytic leukemia, particularly those with specific genetic mutations or a concomitant mast cell clone.
✕Less likely to help
Patients with other types of leukemia or those without chronic myelomonocytic leukemia may not benefit from this research.
What this research studies
This research focuses on chronic myelomonocytic leukemia (CMML), a serious type of leukemia. The team has developed patient-derived xenograft (PDX) models that accurately reflect the disease's characteristics, allowing for better understanding and treatment options. By studying these models, researchers aim to identify new therapies that target specific genetic features and signaling pathways in CMML. The project also explores the interaction between CMML and a unique mast cell clone found in some patients, which may influence disease progression and treatment response.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with chronic myelomonocytic leukemia.
How similar studies have gone: Previous research has shown promise in using patient-derived xenograft models for studying various cancers, indicating that this approach could be effective for CMML as well.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Padron, Eric — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Padron, Eric
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for a blood cancer called CMML (CBL-mutant CMML)
A physician-scientist is testing targeted drugs to treat a hard-to-kill blood cancer called CMML in patients whose cancer has CBL mutations.
-
Understanding how CMML develops and becomes aggressive
Looks at blocking overactive MEK/ERK signals and BET protein-driven gene activity to slow or reverse aggressive CMML and lower its chance of turning into AML for people whose leukemia has NRAS and ASXL1 mutations.
-
Blocking PLK1 in RAS‑mutated chronic myelomonocytic leukemia
People with relapsed or refractory proliferative CMML that has RAS pathway mutations will receive an oral drug called onvansertib that blocks the cell‑division protein PLK1 to look for safety and early signs of benefit.
-
How inflammation changes blood stem cells and drives progression in chronic myelomonocytic leukemia
Looking at whether inflammation changes blood stem cells and speeds disease in adults with CMML.
-
Patient-based mouse models to find better treatments for chronic myelomonocytic leukemia
Researchers are using mice implanted with patients' CMML cells to try out new treatment approaches for people with chronic myelomonocytic leukemia.
-
Understanding how chronic myelomonocytic leukemia resists targeted therapy
This study is looking at how some people with chronic myelomonocytic leukemia (CMML) might not respond to a treatment called cobimetinib, and it aims to help those patients by figuring out why that happens and finding better ways to treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.